Interferon-induced vasospasm in chronic myeloid leukaemia

Acta Haematologica

Volumn 100, Issue 2, 1998, Pages 94-96

  Zeidman, Aliza ^a   Dicker, Dror ^a   Mittelman, Moshe ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b HASHARON HOSPITAL   (Israel)

Author keywords

Chronic myeloid leukaemia; Iloprost; Interferon; Vasospasm

Indexed keywords

ILOPROST; INTERFERON;

ADULT; ANGINA PECTORIS; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; VASOSPASM;

CORONARY VASOSPASM; FEMALE; HEART CATHETERIZATION; HUMANS; INTERFERONS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0031727864     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040874     Document Type: Article

References (18)

1. Freund M, Huber C: Interferon alpha has become a standard in the treatment of chronic myelogenous leukemia. Semin Hematol 1993; 30:1-5.
2. Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alpha 2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820-825.
3. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arther DD, Powell B, Gottlieb A, Peterson BA, Rai K, Testa JR, LeBeau M, Tantravahi R, Bloomfield CD: Prolonged subcutaneous administration of recombinant alpha interferon in patients with previously untreated Philadelphia chromosome positive chronic phase chronic myelogenous leukemia: Effect on remission duration and survival. Cancer and Leukemia Group B study 8583. Blood 1993;82:2975-2984.
4. Talpaz M, Kantarjian HM, McCradie KB, Keating MJ, Trujillo J, Gutterman J: Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69:1280-1288.
5. Guilholt F: The role of Interferon in the treatment of chronic myelogenous leukemia in chronic phase. Hematologie 1994;36:39-46.
6. Conlon KL, Urba WJ, Smith JW: Exacerbation of symptoms of autoimmune disease in patients receiving alpha interferon therapy. Cancer 1990;65:2237-2242.
7. Kruit WH, Punt KJ, Goey SH, Mulder PH, Van Hoogenhuyze DC, Henzen-Logmans SC, Stoter G: Cardiotoxicity as a dose limiting factor in a schedule of high dose bolus therapy with interleukin 2 and alpha-interferon. An unexpectedly frequent complication. Cancer 1994;74:2850-2856.
8. Sonnenblick M, Rosin A: Cardiotoxicity of interferon. Chest 1991;99:557-561.
9. Cohen MC, Humberman MS, Nesto RW: Recombinant alpha-2 interferon related cardiomyopathy. Am J Med 1988;85:549-550.
10. Tanaka H, Yamakado T, Emi Y, Nabeshima K, Itoh S, Nakano T: Interferon induced vasospasm. A case history. Angiology 1995;46: 1139-1143.
11. Doll DC, Yarbro JW: Vascular toxicity associated with antineoplastic agents. Semin Oncol 1992;19:580-596.
12. Grant SM, Goa KL: Iloprost: A review. Drugs 1992;43:889-924.
13. Creutzig A, Freund M: Severe Raynaud's syndrome associated with interferon therapy. Angiology 1996;47:185-187.
14. Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M, Seeber S, Niederle N: Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992;65:70-74.
15. Skurkovich S, Skurkovich B, Bellanti JA: A unifying model of the immunoregulatory role of the interferon system: Can interferon produce disease in humans? Clin Immunol Immunopathol 1987;43:362-373.
16. Creutzig A, Freund M, Caspary L, Alexander K: Microangiopathy in patiens with chronic myelogenous leukemia treated with interferon. Microvasc Res 1996;52:288-292.
17. Goldman JM: New directions for the treatment of chronic myeloid leukemia. Drugs 1995;49: 651-655.
18. Schofield JR, Robinson WA, Murphy JR, Rovira DK: Low doses of interferon are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 1994;121:736-744.